Cellular Biomedicine: World Congress on Cancer Therapy 2015 (Cellular Biomedicine Group) - Nov 5, 2015 - “The EGFR-targeting CART cell therapy for EGFR-positive, advanced, relapsed/refractory solid tumor patients is safe, well tolerated and shows positive signal of clinical activity”
P1/2 data • Oncology
|